Ipsen

Stocks

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-08-06 EDT			5-day change	1st Jan Change
161.90 ^EUR	+1.38%		+2.99%	+36.05%

08-04	Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration	CI
08-03	Jefferies Downgrades Ipsen to Underperform, Boosts PT	MT

Published on 05/18/2026 at 11:35 am EDT - Modified on 05/18/2026 at 07:05 pm EDT

S&P Capital IQ

Presenter Speech
Christelle Huguet (Executives)

Excellent. Thanks, everyone, for joining, and hello. I am pleased to welcome you this afternoon to our corabotase LANTIC Phase II glabellar line KOL

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

08-04	Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration	CI
08-03	Jefferies Downgrades Ipsen to Underperform, Boosts PT	MT
08-03	Middle East hopes lift Europe into the green
08-03	European stock markets start August in a good mood
07-31	Ipsen S.A., H1 2026 Earnings Call, Jul 30, 2026
07-30	Ipsen: Another quarterly beat; 2026 guidance upgraded
07-30	Ipsen S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-30	Ipsen raises its full-year targets
07-30	Ipsen Raises FY26 Sales Growth Outlook	MT
07-29	Ipsen Announces Appointment of Catherine Bradley, CBE, as an Independent Director, Chair of the Audit Committee and Member of the Compensation Committee, Effective July 29, 2026	CI
07-24	Healthcare Shares Benefit From Rotation Away From AI Darlings -- Health Care Roundup	DJ
07-24	Ipsen Provides Update On Phase III BOLD Trial In Biliary Atresia	CI
07-24	SAP maps out gains, Carrefour takes the hit
07-24	Ipsen Says Phase 3 Trial of Bylvay in Biliary Atresia Misses Primary Endpoint	MT
07-22	Ipsen Closes Purchase of Potravitug Developer Memo Therapeutics	MT